Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cvrx, Inc. (CVRX) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Cvrx, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1235912.
Total stock buying since 2021: $25,630,784.
Total stock sales since 2021: $258,651.
Total stock option exercises since 2021: $155,350.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 194,463 | $1,009,309 | 0 | $0 | 0 | $0 |
| 2024 | 38,500 | $322,512 | 7,700 | $171,306 | 18,289 | $43,815 |
| 2023 | 0 | $0 | 1,750 | $31,281 | 12,951 | $34,628 |
| 2022 | 184,420 | $1,278,483 | 4,600 | $56,064 | 101,425 | $69,090 |
| 2021 | 1,278,649 | $23,020,480 | 0 | $0 | 32,636 | $7,817 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 194,463 | $1,009,309 | 0 | $0 | 0 | $0 |
| 2024-11 | 0 | $0 | 1,430 | $19,416 | 2,500 | $12,852 |
| 2024-08 | 38,500 | $322,512 | 0 | $0 | 0 | $0 |
| 2024-03 | 0 | $0 | 0 | $0 | 934 | $221 |
| 2024-02 | 0 | $0 | 6,270 | $151,890 | 8,855 | $29,320 |
| 2024-01 | 0 | $0 | 0 | $0 | 6,000 | $1,422 |
| 2023-12 | 0 | $0 | 0 | $0 | 2,266 | $2,811 |
| 2023-10 | 0 | $0 | 0 | $0 | 778 | $184 |
| 2023-09 | 0 | $0 | 0 | $0 | 5,862 | $12,286 |
| 2023-08 | 0 | $0 | 628 | $11,652 | 0 | $0 |
| 2023-07 | 0 | $0 | 1,122 | $19,629 | 3,750 | $19,278 |
| 2023-05 | 0 | $0 | 0 | $0 | 295 | $69 |
| 2022-11 | 0 | $0 | 4,600 | $56,064 | 9,000 | $46,269 |
| 2022-06 | 0 | $0 | 0 | $0 | 9,585 | $2,271 |
| 2022-05 | 78,853 | $436,458 | 0 | $0 | 0 | $0 |
| 2022-04 | 100 | $597 | 0 | $0 | 17,510 | $4,148 |
| 2022-02 | 105,467 | $841,428 | 0 | $0 | 53,690 | $12,724 |
| 2022-01 | 0 | $0 | 0 | $0 | 11,640 | $3,678 |
| 2021-12 | 0 | $0 | 0 | $0 | 4,630 | $1,096 |
| 2021-11 | 1,175 | $16,909 | 0 | $0 | 28,006 | $6,721 |
| 2021-08 | 625 | $12,328 | 0 | $0 | 0 | $0 |
| 2021-07 | 1,276,799 | $22,989,872 | 0 | $0 | 0 | $0 |
| 2021-06 | 50 | $1,371 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-14 | Nielsen Kirk G. | Buy | 61,200 | 5.24 | 320,382 |
| 2025-05-13 | Jain Mudit K. | Buy | 150 | 5.26 | 789 |
| 2025-05-13 | Nielsen Kirk G. | Buy | 101,413 | 5.29 | 536,271 |
| 2025-05-12 | Jain Mudit K. | Buy | 1,500 | 4.66 | 6,985 |
| 2025-05-12 | Nielsen Kirk G. | Buy | 25,200 | 4.79 | 120,682 |
| 2025-05-12 | Hykes Kevin (PRES & CEO) | Buy | 5,000 | 4.84 | 24,200 |
| 2024-11-19 | Verrastro Paul (CHIEF MKTG & STRAT OFFICER) | Sale | 1,430 | 13.58 | 19,416 |
| 2024-11-19 | Verrastro Paul (CHIEF MKTG & STRAT OFFICER) | Option Ex | 2,500 | 5.14 | 12,852 |
| 2024-08-15 | Slattery Joseph P | Buy | 3,000 | 8.10 | 24,300 |
| 2024-08-08 | Slattery Joseph P | Buy | 3,000 | 8.24 | 24,717 |
| 2024-08-06 | Slattery Joseph P | Buy | 2,500 | 9.09 | 22,725 |
| 2024-08-05 | Hykes Kevin (PRES & CEO) | Buy | 30,000 | 8.36 | 250,770 |
| 2024-03-25 | Palmer Craig E. (SVP, U.S. SALES) | Option Ex | 934 | .24 | 221 |
| 2024-02-29 | Johnson & Johnson Innovation - Jjdc, Inc. | Option Ex | 3,855 | .94 | 3,615 |
| 2024-02-20 | Verrastro Paul (CHIEF MKTG & STRAT OFFICER) | Sale | 2,545 | 21.91 | 55,748 |
| 2024-02-20 | Verrastro Paul (CHIEF MKTG & STRAT OFFICER) | Option Ex | 5,000 | 5.14 | 25,705 |
| 2024-02-16 | Johnson & Johnson Innovation - Jjdc, Inc. | Sale | 3,725 | 25.81 | 96,142 |
| 2024-01-29 | Yared Nadim (CHIEF EXECUTIVE OFFICER) | Option Ex | 6,000 | .24 | 1,422 |
| 2023-12-28 | Slattery Joseph P | Option Ex | 1,950 | 1.40 | 2,737 |
| 2023-12-14 | Behbahani Ali (Director) | Option Ex | 316 | .24 | 74 |
| 2023-10-16 | Galle Liz (VP OF GLOBAL CLINICAL RESEARCH) | Option Ex | 778 | .24 | 184 |
| 2023-09-18 | Oasheim Jared (CHIEF FINANCIAL OFFICER) | Option Ex | 5,862 | 2.10 | 12,286 |
| 2023-08-03 | Verrastro Paul (CHIEF MKTG & STRAT OFFICER) | Sale | 628 | 18.55 | 11,652 |
| 2023-07-31 | Verrastro Paul (CHIEF MKTG & STRAT OFFICER) | Sale | 1,122 | 17.50 | 19,629 |
| 2023-07-31 | Verrastro Paul (CHIEF MKTG & STRAT OFFICER) | Option Ex | 3,750 | 5.14 | 19,278 |
| 2023-05-16 | Palmer Craig E. (SVP, U.S. SALES) | Option Ex | 295 | .24 | 69 |
| 2022-11-28 | Verrastro Paul (CHIEF MKTG & STRAT OFFICER) | Sale | 4,600 | 12.19 | 56,064 |
| 2022-11-28 | Verrastro Paul (CHIEF MKTG & STRAT OFFICER) | Option Ex | 9,000 | 5.14 | 46,269 |
| 2022-06-02 | Oasheim Jared (CHIEF FINANCIAL OFFICER) | Option Ex | 9,585 | .24 | 2,271 |
| 2022-05-24 | Nielsen Kirk G. (Director) | Buy | 8,070 | 5.05 | 40,753 |
| 2022-05-23 | Nielsen Kirk G. (Director) | Buy | 4,432 | 5.04 | 22,337 |
| 2022-05-20 | Nielsen Kirk G. (Director) | Buy | 13,387 | 5.04 | 67,403 |
| 2022-05-19 | Nielsen Kirk G. (Director) | Buy | 10,976 | 5.04 | 55,297 |
| 2022-05-02 | Nielsen Kirk G. (Director) | Buy | 41,988 | 5.97 | 250,668 |
| 2022-04-28 | Nielsen Kirk G. (Director) | Buy | 100 | 5.97 | 597 |
| 2022-04-25 | Yared Nadim (CHIEF EXECUTIVE OFFICER) | Option Ex | 6,059 | .24 | 1,435 |
| 2022-04-22 | Brintnall John (CHIEF STRATEGY OFFICER AND SEC) | Option Ex | 11,451 | .24 | 2,713 |
| 2022-02-28 | Jain Mudit K. | Buy | 600 | 9.03 | 5,419 |
| 2022-02-23 | Nielsen Kirk G. (Director) | Buy | 38,200 | 8.04 | 307,127 |
| 2022-02-22 | Nielsen Kirk G. (Director) | Buy | 40,008 | 7.94 | 317,663 |
| 2022-02-18 | Nielsen Kirk G. (Director) | Buy | 26,659 | 7.92 | 211,219 |
| 2022-02-08 | Bruhn-ding Dean (VP of Reg. Affairs and QA) | Option Ex | 35,000 | .24 | 8,295 |
| 2022-02-03 | Yared Nadim (Chief Executive Officer) | Option Ex | 18,690 | .24 | 4,429 |
| 2022-01-13 | Slattery Joseph P | Option Ex | 11,640 | .32 | 3,678 |
| 2021-12-30 | Brintnall John (Chief Strategy Officer and Sec) | Option Ex | 2,550 | .24 | 604 |
| 2021-12-28 | Yared Nadim (Chief Executive Officer) | Option Ex | 2,080 | .24 | 492 |
| 2021-11-30 | Slattery Joseph P | Option Ex | 3,000 | .24 | 720 |
| 2021-11-24 | Bruhn-ding Dean (VP of Reg. Affairs and QA) | Option Ex | 14,000 | .24 | 3,360 |
| 2021-11-22 | Yared Nadim (Chief Executive Officer) | Option Ex | 11,006 | .24 | 2,641 |
| 2021-11-19 | Jain Mudit K. | Buy | 300 | 13.69 | 4,106 |
| 2021-11-18 | Jain Mudit K. | Buy | 875 | 14.63 | 12,803 |
| 2021-08-12 | Jain Mudit K. | Buy | 625 | 19.73 | 12,328 |
| 2021-07-02 | Pardo Geoffrey B | Buy | 275,000 | 18.00 | 4,950,000 |
| 2021-07-02 | Jain Mudit K. | Buy | 222,222 | 18.00 | 3,999,996 |
| 2021-07-02 | Sandell Scott D (10% Owner) | Buy | 250,250 | 18.00 | 4,504,500 |
| 2021-07-02 | New Enterprise Associates 10 L P (10% Owner) | Buy | 225,500 | 18.00 | 4,059,000 |
| 2021-07-02 | Glaxosmithkline Plc | Buy | 275,000 | 18.00 | 4,950,000 |
| 2021-07-02 | Nehra John M | Buy | 27,777 | 18.00 | 499,986 |
| 2021-07-01 | Jain Mudit K. | Buy | 1,000 | 25.10 | 25,100 |
| 2021-07-01 | Nehra John M | Buy | 50 | 25.80 | 1,290 |
| 2021-06-30 | Nehra John M | Buy | 50 | 27.43 | 1,371 |
Insider trading activities including stock purchases, stock sales, and option exercises of CVRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Cvrx, Inc. (symbol CVRX, CIK number 1235912) see the Securities and Exchange Commission (SEC) website.